OlatoyosiMOdenikeMD

PubMed

• Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
  Farhad Ravandi, Asad Bashey, James M Foran, Wendy Stock, Raya Mawad, Nicholas J Short, Musa Yilmaz, Hagop M Kantarjian, Olatoyosi Odenike, Anand A Patel, Raman Garcha,...> ;Blood Advances. 2023 Aug 30
• Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Cons...
  Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel ...> ;Blood Reviews. 2023 Aug 19
• Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
  Caner Saygin, Giorgia Giordano, Kathryn Shimamoto, Bart Eisfelder, Anika Thomas-Toth, Girish Venkataraman, Vijayalakshmi Ananthanarayanan, Tiffaney L Vincent, Adam DuV...> ;Clinical Cancer Research. 2023 Aug 15
• Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
  Guanghao Liang, Linchen Wang, Qiancheng You, Kirk Cahill, Chuanyuan Chen, Wei Zhang, Noreen Fulton, Wendy Stock, Olatoyosi Odenike, Chuan He, Dali Han> ;Advanced Science. 2023 Aug 1
• 6 citations
  Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
  Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, Jessica K Altman, Amir T Fathi, Olatoyosi Odenike, Gail J Roboz, Kendra Sweet, Crystal Miller, Anders Wennborg...> ;The Lancet. Haematology. 2023 Apr 1
• 1 citations
  Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1International Workshop on MDS (iwMDS) Of t...
  Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, Uma Borate, Jacqueline Boultwood, Andrew M Brunner, Rena Buckstein, Hetty E Carraway, Jane E Churpek, Naval G Daver, ...> ;Blood Reviews. 2023 Jul 1
• 9 citations
  Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
  Amer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Maximilian Stahl, Lionel Adès, Uma Borate, David Bowen, Rena Buckstein, Andrew Brunner, Hetty E Carraway, Naval...> ;Blood. 2023 Apr 27
• SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
  Anand A Patel, Olatoyosi Odenike> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 May 1
• Clinical and molecular response of acute myeloid leukemia harboring non-canonicalN676K driver mutations to contemporary FLT3 inhibitors.
  Gregory W Roloff, Frank Wen, Aubrianna Ramsland, Andrew S Artz, Satyajit Kosuri, Wendy Stock, Olatoyosi Odenike, Richard A Larson, Hongtao Liu, Lucy A Godley, Michael ...> ;Haematologica. 2023 Aug 1
• 1 citations
  Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.
  Mrinal M Patnaik, Amer M Zeidan, Eric Padron, Uwe Platzbecker, David A Sallman, Amy E DeZern, Rafael Bejar, Mikkael Sekeres, Justin Taylor, Richard F Little, Jan P Bew...> ;Leukemia. 2022 Dec 1
• 2 citations
  Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
  Antoine N Saliba, Scott H Kaufmann, Eytan M Stein, Prapti A Patel, Maria R Baer, Wendy Stock, Michael Deininger, William Blum, Gary J Schiller, Rebecca L Olin, Mark R ...> ;Blood Advances. 2023 Jun 13
• 14 citations
  A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
  Amer M Zeidan, Uma Borate, Daniel A Pollyea, Andrew M Brunner, Fernando Roncolato, Jacqueline S Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan...> ;American Journal of Hematology. 2023 Feb 1
• 8 citations
  Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
  Amer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, Mikkael A Sekeres, David P Steensma, Uwe Platzbecker, Sanam Loghavi, Jacqueline Boultwood, Rafael Bejar, John M ...> ;Leukemia. 2022 Dec 1
• 2 citations
  An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.
  Maximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, Michael R Savona, Mina L Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F Sanz, David A Sallman, Vale...> ;Blood Advances. 2023 Jun 27
• 289 citations
  International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
  Daniel A Arber, Attilio Orazi, Robert P Hasserjian, Michael J Borowitz, Katherine R Calvo, Hans-Michael Kvasnicka, Sa A Wang, Adam Bagg, Tiziano Barbui, Susan Branford...> ;Blood. 2022 Sep 15
• 2 citations
  Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.
  Daniel H Albert, Neal C Goodwin, Angela M Davies, Jenny Rowe, Gerold Feuer, Michael Boyiadzis, Kathleen A Dorritie, Maria Mancini, Regina Gandour-Edwards, Brian A Jona...> ;In Vivo. 2022 Jun 23
• 8 citations
  Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022.
  Gregory W Roloff, Olatoyosi Odenike, Ashish Bajel, Andrew H Wei, Nicole Foley, Geoffrey L Uy> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2022 Apr 1
• 1 citations
  Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults.
  Anand Ashwin Patel, Joseph Heng, Emily Dworkin, Sarah Monick, Benjamin A Derman, Adam S DuVall, Sandeep Gurbuxani, Satyajit Kosuri, Hongtao Liu, Michael Thirman, Lucy ...> ;Ejhaem. 2021 Aug 1
• 7 citations
  Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
  Dong Chen, Siyuan Xia, Rukang Zhang, Yuancheng Li, Christopher Famulare, Hao Fan, Rong Wu, Mei Wang, Allen Zhu, Shannon Elf, Rui Su, Lei Dong, Martha Arellano, William...> ;Molecular Cell. 2021 Sep 16
• 27 citations
  Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis
  John Mascarenhas, Rami S. Komrokji, Francesca Palandri, Bruno Martino, Dietger Niederwieser, Andreas Reiter, Bart L. Scott, Maria R. Baer, Ronald Hoffman, Olatoyosi Od...> ;Journal of Clinical Oncology. 2021 Jun 17
• 24 citations
  A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory a...
  Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, David A. Rizzieri, Thomas Prebet, Chris Chen, Relja Popovic, Dimple A. Modi, Rujuta Joshi, Johannes E. A. Wolff, B...> ;Cancer. 2021 May 2
• 11 citations
  Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
  Anand Patel, Kirk E. Cahill, Caner Saygin, Olatoyosi Odenike> ;Blood Advances. 2021 Apr 27
• 3 citations
  OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
  Bartholomew J. Eisfelder, Caner Saygin, Joseph Wynne, Margaret W Colton, Mariafausta Fischietti, Elspeth M. Beauchamp, Jason X. Cheng, Olatoyosi Odenike, Gail J. Roboz...> ;Blood Cancer Journal. 2021 Mar 3
• 34 citations
  Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.
  Sonali M. Smith, Kerri Wachter, Howard A. Burris, Richard L. Schilsky, Daniel J. George, Douglas E. Peterson, Melissa Lynne Johnson, Merry Jennifer Markham, Kathryn Fi...> ;Journal of Clinical Oncology. 2021 Feb 2
• 7 citations
  Genomics of MPN progression.
  Anand Patel, Olatoyosi Odenike> ;Hematology. American Society of Hematology. Education Program. 2020 Dec 4
• Join now to see all

Journal Articles

• How I Treat Blast Phase of Philadelphia-Negative Myeloproliferative Neoplasms  
  Olatoyosi Odenike, MD, Blood
• Clinical Cancer Advances 2015: annual report on progress against cancer from the American Society of clinical oncology  
  Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O’Day SJ, Odenike O, Ryan CJ, Schilsky RL, Sc..., J Clin Oncol, 1/1/2015
• Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including ...  
  Odenike O, Onida F, Padron E, Am Soc Clin Oncol Educ Book, 1/1/2015
• Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies  
  Tallarico M, Odenike O, Curr Hematol Malig Rep, 1/1/2015
• Vosaroxin plus cytarabine versus placebo plus cytarabine nin patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomized, controlled, doub...  
  Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig A, Vey N, Strickland SA, Schiller GJ, , Jabbour E, Erba HP, Pigneux A, Horst A, Recher, C, Klimek, VM, Cortes, J, Feld..., Lancet Oncol, 1/1/2015
• Telomerase Imetestat for patients with essential thrombocythemia  
  Baerlocher G., Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Roth A, ,Daskalakis M, Burington B, Stuart M, Snyder DS, N Engl J Med, 1/1/2015
• T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia  
  Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y, Oncotarget, 1/1/2015
• A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies  
  Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock, W, Investigational New Drugs, 1/1/2015
• Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?  
  Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R, Bone Marrow Transplant, 1/1/2015
• Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myeloid Leukemia (AML): A University of Chicago Phase II Consortium Trial  
  Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison TG, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L..., Clin Cancer Res, 1/15/2014
• Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable remissions with imatinib  
  Cheah CY, Burbury K, Apperly JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, ..., Blood, 1/1/2014
• Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients  
  Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike O, Larson RA, van Besien K, Artz S, Hematologica, 1/1/2014
• Treatment of myeloproliferative neoplasms  
  Yacoub A, Odenike O, Verstovsek S, Current Hem Malig Report, 1/1/2014
• Interim analysis of the safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts  
  Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O’Neil..., J. Hematol Oncol, 1/29/2013
• A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high risk myelodysplastic syndromes  
  Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W, Bone Marrow Transplant, 1/1/2013
• Beyond JAK inhibitor therapy in Myelofibrosis  
  Odenike O, Hematology, 1/1/2013
• Immune Reconstitution after Combined Haploidentical and Umbilical Cord Blood Transplantation  
  Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, W..., Leuk Lymphoma, 1/22/2012
• Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia  
  Jamieson K, Odenike O, Expert Opin Pharmacother, 1/1/2012
• Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia  
  Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O’Brien S, Leuk Lymphoma, 1/1/2012
• Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th...  
  Abel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian J..., Am J Hematol, 1/1/2012
• A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia  
  Hossain, Jain N, McConville J, Anastasi J and Odenike O, Chest, 1/1/2012
• Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia  
  Kantarjian H, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, A..., Invest New Drugs, 1/15/2011
• Allogeneic stem cell transplantation in renal failure Engraftment and Prolonged Survival, but High Incidence of Neurologic Toxicity  
  van Besien K, Schouten V, Parsad S, Smith S, Odenike O, Artz A, Leuk Lymphoma, 1/13/2011
• Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation  
  van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Cerro PD, Larson RA, Artz AS, Biol Blood Marrow Transplant, 1/9/2011
• Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th international post-ASH symposium  
  Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H Gotlib J, Kiladjian J-J, Levine RL, Licht JD, Mullally A, Odenike O, Pardanai A,..., Blood Cancer Journal, 1/1/2011
• Join now to see all

Books/Book Chapters

• Treatment strategies-Hematology 
  Chapter: Targeted therapeutic approaches for myelofibrosis 
  Curran E and Odenike O2014
• Oncology – An Evidence-Based Approach 
  Chapter: Acute Lymphoblastic Leukemia 
  Page 1173 - 2000Odenike OM, Michaelis L, Stock WEditors: Chang AE, Ganz PA, Hayes DF, Kinsella T, Pass HI, Schiller JH, Stone R, Stretcher.Edition 1st,2006
• Griffith’s 5-minute Clinical Consult 
  Chapter: Myeloproliferative diseases 
  Page 736 - 737Odenike OMEditors: Mark R. Dambro.Edition 13th,2005
• Oncologic Therapies 
  Chapter: Chronic lymphocytic leukemia 
  Page 231 - 242Odenike OM, Larson RAEditors: E.E. Vokes and HM Golomb.Edition 2nd,2003
• Cancer Medicine 
  Chapter: Recurring chromosome rearrangements in human cancer 
  Page 88 - 107Olopade OI, Sobulo OM, Rowley JDEditors: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, and Frei E.Edition 5th,2000
• Contemporary Management of Myeloproliferative Neoplasms 
  Chapter: Myelofibrosis: Risk stratification and therapeutic strategies 
  Jasielec J and Odenike OEditors: Stein BL and McMahon B.
• Join now to see all

Abstracts/Posters

• Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Biomarker Modulation By Mivebresib (ABBV-075) +/_ Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long term Results in Myeloproliferative Neoplasms and Myelodysplastic Syndromes
  Odenike OM, ASCO poster discussion session- Leukemia, Myelodysplasia and Transplantation track, 1/1/2016
• CML and Ph- Myeloproliferative Diseases
  Odenike OM, ASCO Annual Meeting, Chicago, IL, 1/1/2011
• Join now to see all

Lectures

• Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute ... 
  2019 ASCO Annual Meeting - 6/1/2019
• A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Rela... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Imetelstat, what is the best setting? 
  Dallas, TX - 1/1/2016
• Targeted therapies in Myelofibrosis 
  Boston University, Boston, MA - 1/1/2016
• Clonal Hematopoiesis and how it can confound the results of germline and somatic mutation testing 
  1/1/2016
• Update on targeted therapies in acute and chronic leukemias 
  Lombard, IL - 1/1/2015
• MDS Intergroup Trial 
  Multiple locations, 2011 2012, 2014, 2015 - 1/1/2015
• Frontline Therapies in Myelodysplastic Syndrome 
  Chicago, IL - 1/1/2015
• Leukemia Track/Myelodysplasia track 
  Chicago, IL - 1/1/2015
• S Focus on Myeloproliferative Neoplasm & Myelodysplastic Syndrome 
  Alexandria, VA - 1/1/2015
• Novel Therapies in Myelofibrosis 
  San Diego, CA - 1/1/2015
• Myelofibrosis: Pathogenesis, Novel therapeutic approaches 
  Philadelphia, PA - 1/1/2015
• Myelodysplastic Syndromes, Concept in Development 
  Chicago, IL - 1/1/2015
• Myelodysplastic Syndromes- Molecular Pathogenesis and novel treatment options 
  Tzaizhou Province, China - 1/1/2015
• RAS as a therapeutic target in AML 
  Chicago, IL - 1/1/2014
• Therapeutic Targeting of Epigenetic changes in myeloid neoplasms 
  Chicago, IL - 1/1/2014
• Myeloproliferative Neoplasms 
  Atlanta, GA, 2014; Seattle, WA, 2014 - 1/1/2014
• Beyond JAK inhibitors in Myelofibrosis 
  Mexico City, Mexico - 1/1/2014
• US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 
  Dana Point, CA - 1/1/2014
• Myelodysplastic Syndromes “Where do we go from here?” 
  Chicago, IL - 1/1/2014
• Epigenetic Therapy in MPNs 
  San Francisco, CA - 1/1/2014
• Targeted Therapies in Leukemia/Myeloid Neoplasia 
  Chicago, IL - 1/1/2013
• Personalized Treatment Options for Acute and Chronic Leukemias and Lymphoma 
  1/1/2013
• Beyond ruxolitinib therapy in Myelofibrosis 
  1/1/2013
• Update on the Biology and Treatment of Myeloproliferative Neoplasms 
  Advocate Lutheran General hospital - 1/1/2013
• Join now to see all

Other

• ”Ibrutinib will change the CLL landscape” Expert opinion on CLL Resonate Ibrutinib study 
  Oncology times
  1/1/2014
• It takes more than a JAK-hammer to crack the case 
  ASH News Daily
  1/1/2013
• Nature Reviews Drug Discovery 10: 717-18, Companies hope for kinase inhibitor JAKpot 
  News and Analysis
  1/1/2011
• Early Clinical Finding with JAK2 Inhibition in Myelofibrosis 
  The ASCO Post
  1/1/2011
• Expert opinion on chemotherapy+imatinib in Ph+ acute lymphoblastic leukemia (Interview) 
  The ASCO Post
  1/1/2010
• Novel therapeutic approaches for Myelofibrosis with Myeloid Metaplasia 
  Odenike OM, ASCO Educational Book
  www.asco.org
  1/1/2007
• Join now to see all